ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced today that founder and CEO Michael D. West, PhD will deliver a presentation titled “The Age-Related Metabolic Program” as part of a session at Metabesity 2019, October 15-16 in Washington, DC.
Details of the session follow.
Wednesday, October 16
Carnegie Institution for Science
1530 P Street NW
Washington, DC 20005
9:40-10:45am – Panel Session: Clinical Development Issues – Challenges and Opportunities
Dr. West will be joined on the panel by:
- Nir Barzilai, MD, Director of the Institute for Aging Research at Albert Einstein College of Medicine
- William Cefalu, MD, Director of the Division of Diabetes, Endocrinology & Metabolic Diseases, NIDDK/NIH
- Alex Zhavoronkov, PhD, CEO of InSilico Medicine (which has collaborated with AgeX in relation to AgeX’s induced tissue regeneration program)
- Moderator: Jay Skyler, MD, MACP, Professor of Medicine, Pediatrics and Psychology at the University of Miami
The full event program is available here.
A copy of the presentation will be available on the Investors section of the company’s website at www.agexinc.com.
About AgeX Therapeutics
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem® and UniverCyte™ manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a whole host of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeX’s revolutionary longevity platform named induced Tissue Regeneration (iTR™) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem® is AgeX’s delivery technology to stably engraft PureStem cell therapies and slowly release iTR molecules in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan, and is seeking opportunities to form licensing and partnership agreements around its broad IP estate and proprietary technology platforms for non-core clinical applications.
Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in AgeX’s reports filed with the Securities and Exchange Commissions (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.